BamSEC and AlphaSense Join Forces
Learn More

Aclaris Therapeutics Inc.

NASDAQ: ACRS    
Share price (1/8/25): $2.46    
Market cap (1/8/25): $176 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 8-K 11 pages Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.5
from 8-K 12 pages Aclaris Therapeutics, Inc. 2024 Inducement Plan Stock Option Grant Notice
12/34/56
EX-10.4
from 8-K 20 pages Aclaris Therapeutics, Inc. 2024 Inducement Plan Adopted by the Board of Directors: November 16, 2024
12/34/56
EX-10.3
from 8-K 18 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 15 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 47 pages Royalty Purchase Agreement ​ ​ ​ ​ Aclaris Therapeutics, Inc. as Seller ​ ​ ​ - And - ​ ​ ​ Ocm Ip Healthcare Portfolio LP as Purchaser ​ ​ ​ ​ July 16, 2024 ​ ​
12/34/56
EX-10.22
from 10-K 3 pages ​ January 31, 2024 ​ via Email Neal Walker ​ Dear Neal: ​ This Agreement Contains the Terms of Your Position as Interim Chief Executive Officer and President (The “Interim CEO”) of Aclaris Therapeutics, Inc. (The “Company”) With an Effective Date of January 17, 2024. ​
12/34/56
EX-10.18
from 10-K 9 pages Separation Agreement, Waiver and Release
12/34/56
EX-10.15
from 10-K 18 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 18 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 76 pages Paragraph‌page
12/34/56
EX-10.4
from 10-Q 2 pages Aclaris Therapeutics, Inc. Ninth Amended & Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 2 pages Amendment No. 1 to Consulting Services Agreement ​
12/34/56
EX-10.24
from 10-K 17 pages Employment Agreement
12/34/56
EX-10.23
from 10-K 17 pages Amended and Restated Employment Agreement
12/34/56
EX-10.19
from 10-K 10 pages Consulting Services Agreement
12/34/56
EX-10.18
from 10-K 13 pages December 9, 2022 ​ Frank Ruffo ​ ​ Re: Separation Agreement and General Release Dear Frank,
12/34/56
EX-10.1
from 8-K 40 pages Aclaris Therapeutics, Inc. Shares of Common Stock ($0.00001 Par Value Per Share) Sales Agreement
12/34/56
EX-10.16
from 10-K 2 pages ​ ​ Neal Walker ​ Dear Neal
12/34/56